JPMorgan Chase & Co. Forecasts Strong Price Appreciation for CONMED (NYSE:CNMD) Stock

CONMED (NYSE:CNMD) had its price objective lifted by JPMorgan Chase & Co. from $45.00 to $50.00 in a report released on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 9.80% from the stock’s previous close.

A number of other research analysts also recently commented on CNMD. Wall Street Zen raised shares of CONMED from a “hold” rating to a “buy” rating in a research report on Monday, July 20th. BMO Capital Markets started coverage on CONMED in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 target price on the stock. Wells Fargo & Company raised their price target on CONMED from $46.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Thursday. Zacks Research raised shares of CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 21st. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $44.00.

CONMED Price Performance

Shares of CNMD traded down $0.22 during trading hours on Thursday, hitting $45.54. 482,035 shares of the company were exchanged, compared to its average volume of 506,536. CONMED has a one year low of $31.44 and a one year high of $53.66. The company has a market capitalization of $1.36 billion, a PE ratio of 24.61, a PEG ratio of 2.25 and a beta of 0.94. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.48 and a quick ratio of 0.69. The firm has a fifty day simple moving average of $47.32 and a 200-day simple moving average of $41.43.

CONMED (NYSE:CNMD) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The company had revenue of $335.56 million during the quarter, compared to analyst estimates of $336.28 million. During the same period in the prior year, the firm earned $1.08 earnings per share. The business’s quarterly revenue was down .7% on a year-over-year basis. As a group, sell-side analysts predict that CONMED will post 4.54 earnings per share for the current year.

Institutional Investors Weigh In On CONMED

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNMD. Choreo LLC raised its position in CONMED by 3.0% in the 3rd quarter. Choreo LLC now owns 16,571 shares of the company’s stock worth $766,000 after purchasing an additional 480 shares during the last quarter. Signaturefd LLC boosted its stake in shares of CONMED by 82.7% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock valued at $25,000 after purchasing an additional 248 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of CONMED during the second quarter worth approximately $207,000. Integrated Wealth Concepts LLC acquired a new position in CONMED in the second quarter valued at approximately $41,000. Finally, Allworth Financial LP grew its holdings in CONMED by 1,376.5% during the 2nd quarter. Allworth Financial LP now owns 1,447 shares of the company’s stock worth $47,000 after acquiring an additional 1,349 shares during the period.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED earned $1.04 per share, exceeding the analyst consensus of $1.00. The company also reported that third-quarter profit increased and updated its 2026 outlook. CONMED Q3 Profit Rises, Updates 2026 Guidance
• Positive Sentiment: Wells Fargo raised its price target for CONMED from $46 to $49 while maintaining an “equal weight” rating. The higher target suggests analysts see some upside, although the unchanged rating signals limited conviction. Wells Fargo CONMED Rating
• Neutral Sentiment: Third-quarter revenue of $335.56 million was broadly in line with expectations of $336.28 million. Management’s earnings call and results release provide additional detail on the company’s operating performance and 2026 guidance. CONMED Third-Quarter 2026 Financial Results
• Negative Sentiment: Revenue declined approximately 0.7% year over year, while EPS fell from $1.08 in the same quarter last year to $1.04. This indicates that the earnings beat was driven against expectations rather than underlying year-over-year growth. CONMED Q3 Earnings Top Estimates

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.